An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses.
We have developed a unique multiple step procedure to inactivate human immunodeficiency virus chemically with a very high safety margin while retaining antigenically active structural virion proteins, including gp120, in the final immunogen. The whole virus preparation (1-10 micrograms per dose) was highly immunogenic in a variety of small mammals and induced antibodies that recognized homologous and heterologous strains of HIV-1. Sera from immunized animals bound to peptides representing the entire sequence of the external glycoprotein gp120. Neutralizing antibodies active against the homologous immunizing strain and against heterologous HIV-1 strains were also elicited. Sera with virus neutralizing activity did not bind to MHC class I proteins derived from the human cell line used to grow the virus.
Race
E
E
Department of Academic Virology and Retroscreen Ltd, London Hospital Medical College, Whitechapel, UK.
Frezza
P
P
Stephens
D M
DM
Davis
D
D
Polyanskaya
N
N
Cranage
M
M
Oxford
J S
JS
D016915:AIDS Vaccines / Q000276:immunology*; D000595:Amino Acid Sequence; D000818:Animals; D000917:Antibody Formation; D004306:Dose-Response Relationship, Immunologic; D006168:Guinea Pigs; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015497:HIV-1; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D010455:Peptides / Q000276:immunology; D011817:Rabbits; D051381:Rats; D011994:Recombinant Proteins / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology
D016915:AIDS Vaccines; D015699:HIV Envelope Protein gp120; D010455:Peptides; D011994:Recombinant Proteins; D015164:Vaccines, Inactivated